SEARCH

SEARCH BY CITATION

References

  • 1
    Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. [Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies)]. Clin Immunol 1999; 93:190197.
  • 2
    Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 2002; 109:10011004.
  • 3
    Favre O, Leimgruber A, Nicole A, Spertini F. Intravenous immunoglobulin replacement prevents severe and lower respiratory tract infections, but not upper respiratory tract and non-respiratory infections in common variable immune deficiency. Allergy 2005; 60:385390.
  • 4
    Quinti I, Soresina A, Guerra A et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol 2011; 31:315322.
  • 5
    Chapel H, Lucas M, Lee M et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008; 112:277286.
  • 6
    Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol 2011; 139:133141.
  • 7
    Chapel H, Lucas M, Patel S et al. Confirmation and improvement of criteria for clinical phenotyping in common variable immunodeficiency disorders in replicate cohorts. J Allergy Clin Immunol 2012; 130:11978.e9.
  • 8
    Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010; 125:13541360.e4.
  • 9
    Thépot S, Malphettes M, Gardeur A et al. Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels. J Clin Immunol 2010; 30:602606.
  • 10
    Brambell FW, Hemmings WA, Morris IG. A thoretical model of gamma-globulin catabolism. Nature 1964; 203:13521354.
  • 11
    Simister NE, Mostov KE. An Fc receptor structurally related to MHC class I antigens. Nature 1989; 337:184187.
  • 12
    Kuo TT, Baker K, Yoshida M et al. Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol 2010; 30:777789.
  • 13
    Kim J, Hayton WL, Robinson JM, Anderson CL. Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin Immunol 2007; 122:146155.
  • 14
    Baker K, Qiao S-W, Kuo T et al. Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn. Semin Immunopathol. 2009; 31:223236.
  • 15
    Spiekermann GM, Finn PW, Ward ES et al. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med 2002; 196:303310.
  • 16
    Akilesh S, Christianson GJ, Roopenian DC, Shaw AS. Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J Immunol 2007; 179:45804588.
  • 17
    Sachs UJH, Socher I, Braeunlich CG, Kroll H, Bein G, Santoso S. A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor alpha-chain promoter. Immunology 2006; 119:8389.
  • 18
    Oksenhendler E, Gérard L, Fieschi C et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis 2008; 46:15471554.
  • 19
    Roifman CM, Gelfand EW. Replacement therapy with high dose intravenous gamma-globulin improves chronic sinopulmonary disease in patients with hypogammaglobulinemia. Pediatr Infect Dis J 1988; 7:S9296.
  • 20
    Eijkhout HW, van Der Meer JW, Kallenberg CG et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med 2001; 135:165174.
  • 21
    Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am 2008; 28:779802.
  • 22
    Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol 2010; 137:2130.
  • 23
    Haddad E, Berger M, Wang ECY, Jones CA, Bexon M, Baggish JS. Higher doses of subcutaneous IgG reduce resource utilization in patients with primary immunodeficiency. J Clin Immunol 2012; 32:281289.
  • 24
    Cunningham-Rundles C. How I treat common variable immune deficiency. Blood 2010; 116:715.
  • 25
    Waldmann TA. Disorders of immunoglobulin metabolism. N Engl J Med 1969; 281:11701177.
  • 26
    Andersen SB. Metabolism of gamma-SS globulin in secondary hypogammaglobulinemia. Am J Med 1963; 35:708714.
  • 27
    Wedgwood RJ. Distribution and catabolism of IVIg preparations in immunodeficient patients. In: Imbach P , ed. Immunotherapy with intravenous immunoglobulins. London: Academic Press, 1991:3744.
  • 28
    Cunningham-Rundles C. Lung disease, antibodies and other unresolved issues in immune globulin therapy for antibody deficiency. Clin Exp Immunol 2009; 157 (Suppl. 1):1216.
  • 29
    Freiberger T, Grodecká L, Ravcuková B et al. Association of FcRn expression with lung abnormalities and IVIG catabolism in patients with common variable immunodeficiency. Clin Immunol 2010; 136:419425.